Shrinking Losses At Suzhou Ribo Life Science (SEHK:6938) Test Bearish Profitability Narratives

Setting the Scene: Suzhou Ribo Life Science's Latest Numbers

Suzhou Ribo Life Science (SEHK:6938) has posted another loss for FY 2025, with first half revenue of ¥103.8 million and a basic EPS loss of ¥0.68, while trailing twelve month revenue sits at ¥148.5 million against a TTM EPS loss of ¥2.11. Looking back, revenue has moved from ¥66.3 million in 1H 2024 to ¥76.3 million in 2H 2024 and then to ¥103.8 million in 1H 2025, while basic EPS losses over these halves have gone from ¥1.07 to ¥1.03 and then to ¥0.68. This gives investors a combination of an expanding top line and still heavy losses that keep margins firmly in the red.

See our full analysis for Suzhou Ribo Life Science.

With the headline figures on the table, the next step is to see how these results line up with the most widely held narratives around Suzhou Ribo Life Science, and where the numbers start to challenge those stories.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM loss of ¥278.1 million highlights profit gap

• On a trailing 12 month basis, Suzhou Ribo Life Science booked total revenue of ¥148.5 million against a net loss of ¥278.1 million and a basic EPS loss of ¥2.11, which keeps profitability far behind the current revenue base.
• Critics with a bearish tilt point to this scale of loss as a core issue, and the data backs that concern in several ways:
  • Half year net losses of ¥137.5 million, ¥132.6 million and ¥88.1 million across 1H 2024, 2H 2024 and 1H 2025 show that, even as revenue changes, net income remains firmly negative.
  • Forecasts calling for earnings to decline by about 18.8% per year over the next three years and continued unprofitability are directly in line with this pattern of large trailing 12 month losses.

4.1% revenue growth vs ~19.6% forecast

• Over the last 12 months, revenue grew by about 4.1%, while analyst forecasts point to roughly 19.6% annual revenue growth looking ahead, so expectations for the top line sit well above the recent trailing pace.
• For a more bullish angle, it is notable how this revenue story sits next to the loss profile:
  • The step up in half year revenue from ¥66.3 million in 1H 2024 to ¥76.3 million in 2H 2024 and then ¥103.8 million in 1H 2025 is consistent with the idea of a business that is building sales even while it is loss making.
  • At the same time, the trailing 12 month revenue figure of ¥148.5 million is still far below the ¥278.1 million trailing 12 month loss, which means any bullish view is leaning heavily on that ~19.6% revenue growth forecast rather than current profit metrics.

Negative equity and P/B of 87.9x

• The company reports negative equity, which feeds into a P/B ratio of 87.9x on a negative book value, a very different profile compared with typical industry and peer averages that use positive equity bases.
• Bears argue that this balance sheet position represents a key risk, and the figures anchor that view quite clearly:
  • Ongoing net losses of ¥278.1 million over the trailing 12 months and forecasts for continued losses over at least three years help explain why equity has moved into negative territory.
  • With the share price at ¥54.85 versus an analyst target of ¥102.18, the implied upside sits alongside this negative book value, which can make valuation feel heavily dependent on future revenue delivery rather than current capital strength.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Suzhou Ribo Life Science's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With sentiment split between heavy losses and growth expectations, it helps to look at the figures yourself and decide how comfortable you are with that trade off. To get a clearer picture of both the potential upside and the issues investors are worried about, take a closer look at the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Suzhou Ribo Life Science combines heavy TTM losses of ¥278.1 million, negative equity and a P/B of 87.9x, which leaves its balance sheet looking fragile.

If that kind of financial strain makes you cautious, it is worth spending a few minutes with the solid balance sheet and fundamentals stocks screener (382 results) to focus on companies backed by stronger fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com